Class Action Filed Against Vistagen Therapeutics

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 4d ago

0mins

VTGN+11.49%

Should l Buy VTGN?

Source: PRnewswire

Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of those who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, indicating significant legal risks that could undermine shareholder confidence.
Allegations of Misrepresentation: The lawsuit alleges that Vistagen misled investors regarding the efficacy of its Fasedienol clinical trial, causing shareholders to buy stock at artificially inflated prices, highlighting serious deficiencies in the company's disclosure practices.
Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial did not achieve statistically significant improvement on the primary endpoint, resulting in a dramatic stock price drop from $4.36 to $0.86, a decline of over 80%, reflecting extreme market pessimism about the company's future.
Investor Action Recommendations: Investors are advised to submit their applications to serve as lead plaintiffs in the class action by March 16, 2026, indicating that while participation in the case is not required for recovery, the need for improved corporate governance and shareholder rights remains critical.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.

VTGN

$0.5632+Infinity%1D

Analyst Views on VTGN

Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 0.97 USD with a low forecast of 0.90 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

0 Buy

5 Hold

0 Sell

Hold

Current: 0.505

Low

0.90

Averages

0.97

High

1.00

Current: 0.505

Low

0.90

Averages

0.97

High

1.00

Lucid Capital

Buy

Neutral

downgrade

$19 -> $1

2025-12-17

Reason

Lucid Capital

Price Target

$19 -> $1

AI Analysis

2025-12-17

downgrade

Buy

Neutral

Reason

Lucid Capital downgraded Vistagen to Neutral from Buy with a price target of $1, down from $19. The company announced that its Phase 3 PALISADE-3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder failed to meet its primary endpoint, the analyst tells investors in a research note. The firm says that given the failure of the PALISADE-3 trial, there is "significant uncertainty" surrounding the likelihood of success for the ongoing PALISADE-4 study, which employs an identical design.

Stifel

Buy

Hold

downgrade

$12 -> $1

2025-12-17

Reason

Stifel

Price Target

$12 -> $1

2025-12-17

downgrade

Buy

Hold

Reason

Stifel downgraded Vistagen to Hold from Buy with a price target of $1, down from $12.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VTGN

Unlock Now

About VTGN

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Class Action Lawsuit Against Vistagen Therapeutics Announced

2 days agoGlobenewswire

Class Action Reminder: The Schall Law Firm has announced a class action lawsuit against Vistagen Therapeutics for violations of securities laws, urging investors who traded between April 1, 2024, and December 16, 2025, to contact them by March 16, 2026, to participate.
False Statements Allegation: The complaint alleges that Vistagen misled investors regarding the success of its fasedienol drug candidate by creating a false impression of positive results from the PALISADE-2 trial, resulting in significant investor losses when the truth emerged.
Legal Consultation Offer: The Schall Law Firm offers free legal consultations to affected investors, encouraging them to discuss their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
Certification Status: The class action has not yet been certified, meaning investors are not currently represented by an attorney, and those who choose not to act will remain absent class members, underscoring the importance of timely participation.

Faruqi & Faruqi Investigates Claims Against Vistagen Investors

2 days agoPRnewswire

Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against Vistagen Therapeutics, Inc., focusing on investors who purchased securities between April 1, 2024, and December 16, 2025, indicating possible legal risks for the company.
Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their legal rights.
Direct Contact Channels: Investors can directly contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information on their claims options, ensuring timely communication of critical information.
Potential Impact Assessment: This investigation may negatively affect Vistagen's stock price and investor confidence, prompting investors to closely monitor developments to adjust their investment strategies accordingly.

Vistagen Faces Class Action Lawsuit as Stock Plummets Over 80%

3 days agoGlobenewswire

Class Action Notification: Levi & Korsinsky LLP has informed investors of Vistagen Therapeutics about a class action lawsuit due to alleged securities fraud occurring between April 2024 and December 2025, aiming to recover losses for affected investors.
Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial did not achieve statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, representing a decline of over 80%, which severely impacted investor confidence.
Legal Deadline: Investors who suffered losses must request to be appointed as lead plaintiff by March 16, 2026, to participate in any potential recovery, with no out-of-pocket costs required, thus lowering the barrier for investor participation.
Law Firm's Credentials: With 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has been recognized for seven consecutive years as one of the top securities litigation firms in the U.S., showcasing its expertise in complex cases.

Vistagen Therapeutics Shareholder Notice

3 days agoPRnewswire

Lawsuit Notice: The Gross Law Firm has issued a notice to shareholders of Vistagen Therapeutics, urging those who purchased shares between April 1, 2024, and December 16, 2025, to contact the firm regarding potential lead plaintiff status for recovery.
Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial did not achieve statistical significance on its primary endpoint, causing the stock price to plummet from $4.36 to $0.86, a decline exceeding 80%, which severely undermined investor confidence.
Shareholder Registration Deadline: Shareholders must register by March 16, 2026, to participate in the class action lawsuit, and upon registration, they will receive real-time updates on the case's progress, ensuring their rights are protected throughout the litigation process.
Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors who have suffered losses due to false statements and unethical business practices, emphasizing the need for companies to adhere to responsible business practices.